Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 176.25M P/E - EPS this Y 23.70% Ern Qtrly Grth -
Income -142.38M Forward P/E -1.36 EPS next Y 43.20% 50D Avg Chg -28.00%
Sales 4.42M PEG - EPS past 5Y - 200D Avg Chg -50.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -88.00%
Recommedations 3.00 Quick Ratio 7.18 Shares Outstanding 83.46M 52W Low Chg 1.00%
Insider Own 21.08% ROA -38.46% Shares Float 28.89M Beta 1.26
Inst Own 54.16% ROE -69.76% Shares Shorted/Prior 1.68M/1.66M Price 2.14
Gross Margin - Profit Margin - Avg. Volume 317,417 Target Price 1.66
Oper. Margin -17,977.58% Earnings Date May 2 Volume 256,526 Change -5.73%
About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Biopharmaceuticals, Inc. News
04/05/24 NGM Bio Announces Closing of Tender Offer
04:30 PM NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
03/11/24 NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
03/11/24 NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
03/07/24 Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
02/26/24 NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
02/26/24 NGM to go private through deal with investment firm
02/20/24 NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
01/17/24 NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
01/09/24 NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
01/03/24 Great week for NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) institutional investors after losing 75% over the previous year
11/22/23 Here's Why We're A Bit Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Situation
11/13/23 NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
11/07/23 NGM Bio to Participate in Upcoming Investor Conferences
11/02/23 NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial Results
11/02/23 NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
11/02/23 NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
10/11/23 NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
09/27/23 Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel Medicines
09/20/23 Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
NGM Chatroom

User Image J_Roberts Posted - 1 month ago

$NGM And that was that. There’s obviously things going on here that are way above my head. Time will tell exactly what, but I’m sure TCG and affiliates will be more than happy when payday comes.

User Image Stock_Titan Posted - 1 month ago

$NGM NGM Bio Announces Closing of Tender Offer https://www.stocktitan.net/news/NGM/ngm-bio-announces-closing-of-tender-0cz420vju6fb.html

User Image tradethehalt Posted - 1 month ago

$NGM trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $1.55 Vol: 2.39M.

User Image Scientwist Posted - 03/27/24

@Biotechster $NGM Holding out means missing a guaranteed profit, facing delisting risks, and losing liquidity when NGM Bio becomes a private company.

User Image SigmundFraud Posted - 03/22/24

$NGM Any law firm which responds to this solicitation, I have information which may be relevant to your claims. Message me and my attorney will contact you….

User Image Stock_Titan Posted - 1 month ago

$NGM NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting https://www.stocktitan.net/news/NGM/ngm-bio-to-present-two-posters-highlighting-clinical-data-from-the-6kycxr7ga5ij.html

User Image Biotechster Posted - 2 months ago

$NGM i voted NO on the buyout tender offer

User Image Stockboi_ Posted - 2 months ago

$NGM scratch this idea. Forgot about the buy out.

User Image Stockboi_ Posted - 2 months ago

$NGM interesting levels to pop from

User Image Smith3_1 Posted - 2 months ago

$NGM https://twitter.com/GrantedPatents/status/1768339769908441329?t=7zOYZa_taj18KqPFRMrETw&s=19

User Image AboveNBeyond Posted - 2 months ago

$NGM Is something else going on good here? That caused the spike.

User Image epsguid Posted - 2 months ago

$NGM reported a loss of $0.33, consensus was ($0.37) via @eWhispers #epsbeat http://eps.sh/d/ngm

User Image DonCorleone77 Posted - 2 months ago

$NGM NGM Biopharmaceuticals reports Q4 EPS (33c), consensus (39c) Cash, cash equivalents, and short-term marketable securities were $144.2M as of December 31."In 2023, we made significant progress in patient enrollment in trials of our solid tumor drug candidates. Most notably, we are encouraged by the signals of activity observed in our NGM707 Phase 1b trial, particularly among MSS CRC patients whose lesions are typically unresponsive to immuno-checkpoint therapies. We also made progress in our discussions with the FDA regarding the design of a potential registrational Phase 2 study of aldafermin in PSC using a primary endpoint composed of surrogate biomarkers of PSC progression and obtained orphan drug designation from the agency for aldafermin for the treatment of PSC," said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM Bio. "In 2024, we are focused on completing patient enrollment for NGM707 with a potential interim Phase 1b trial readout in the middle of the year..

User Image Stock_Titan Posted - 2 months ago

$NGM NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/NGM/ngm-bio-provides-recent-business-highlights-and-reports-fourth-v5vv0jbp9qji.html

User Image Geegaa Posted - 2 months ago

$NGM Nice lvl2 chart , moved my funds from $MLGO to here

User Image ZeroJobZeroProblem Posted - 02/29/24

$NGM Is there a reason to wait on selling my stash of this? If I sell now: Pros: I can put that money to work elsewhere I can maybe get over that they screwed the shareholders. Cons: Maybe the deal goes south and a better deal is brought in that shareholders would actually like. Maybe I lose my right to a class action or to go after them directly for gross negligence of fiduciary duties, since it is their responsibility to consider all relevant information before moving forward with a business decision, the duty of loyalty to act in the best interests of the shareholders. Thoughts?

User Image SigmundFraud Posted - 02/28/24

$NGM TCG has controlled this company for years……. Is anybody really surprised they wrap up a losing streak by ingesting the company for Less than Cash?

User Image Ninja_Tradez Posted - 02/28/24

📢 $NGM - TD Cowen Downgrades NGM Biopharmaceuticals to Market Perform, Lowers Price Target to $1.55 https://newsfilter.io/a/12cacc5762d9e8a9bfc905a65de5f00c

User Image AnaChart Posted - 02/28/24

$NGM https://anachart.com/wp-content/uploads/ana_temp/1709121718_soc-img.jpg

User Image LTtrader04 Posted - 02/27/24

$NGM honest question for those who understand M&A and read through the partnerships or merger who what ever you call it. Their drug can save lives. Is there any reason what you can think of that $1.55 per share is a fair or reasonable price ? Is there anything we are missing here ? Or this is true criminal to sell such drug and company at $132mil.

User Image FloatTrip Posted - 02/27/24

$NGM "No-Good-Money" (NGM)

User Image TegridyStocks Posted - 02/27/24

$VKTX After the the party it’s the after party 🎊 But where? $ALT $IOVA $NGM

User Image nickpd Posted - 02/27/24

$NGM What Column Group is trying to steal is the drug NGM707. This drug has cured patient that failed everything when it was combined with Keytruda. Everyone should lawyer up and sue them.

User Image hardrock2112 Posted - 02/27/24

$NGM https://www.brodskysmith.com/cases/ngm-biopharmaceuticals-inc-nasdaq-ngm/

User Image hardrock2112 Posted - 02/27/24

$NGM From Yahoo Finance article: "While we don’t have the same amount of info as the special committee, the strategic decision seems mistimed and $1.55 price seems low," wrote Steven Seedhouse, an analyst at Raymond James, in a note to clients Monday.

User Image hardrock2112 Posted - 02/27/24

$NGM comparatively few sells after those huge buys

User Image hardrock2112 Posted - 02/27/24

$NGM 3PM huge buys near the low..

User Image hardrock2112 Posted - 02/27/24

$NGM I've already factored in my loss at 1.55, so I just pushed my ask way up, just in case legal told them this is a no-no and we are headed back up... (wishful thinking?)

User Image hardrock2112 Posted - 02/27/24

$NGM or its a fake out to unload shares bought at 1.53-1.54

User Image bhg1991 Posted - 02/27/24

$NGM Nice , i planned to Sell in a few minutes :D

Analyst Ratings
Raymond James Market Perform Mar 12, 24
TD Cowen Market Perform Feb 28, 24
B. Riley Securities Buy Nov 22, 23
Citigroup Buy May 3, 23
B. Riley Securities Buy Mar 30, 23
Raymond James Outperform Nov 4, 22
Cowen & Co. Outperform Oct 18, 22
Goldman Sachs Neutral Oct 18, 22
Raymond James Outperform Oct 18, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
COLUMN GROUP L P Director Director Jan 23 Buy 4.9994 9,900 49,494 742,959 01/25/23
GOEDDEL DAVID V Director Director Jan 23 Buy 4.9994 9,900 49,494 742,959 01/25/23
COLUMN GROUP L P Director Director Oct 25 Buy 4.8 123,820 594,336 123,820 10/27/22
GOEDDEL DAVID V Director Director Oct 25 Buy 4.8 123,820 594,336 123,820 10/27/22
GOEDDEL DAVID V Director Director Oct 17 Buy 3.49 130,000 453,700 190,000 10/19/22
COLUMN GROUP L P Director Director Jun 09 Buy 13.5 984,161 13,286,174 90,442 06/13/22
COLUMN GROUP L P Director Director May 26 Buy 13.47 22,911 308,611 51,760 05/31/22
COLUMN GROUP L P Director Director May 11 Buy 11.62 166,350 1,932,987 37,308 05/13/22
GOEDDEL DAVID V Director Director May 11 Buy 11.62 166,350 1,932,987 37,308 05/13/22
COLUMN GROUP L P Director Director May 09 Buy 11.08 114,440 1,267,995 31,818 05/11/22
GOEDDEL DAVID V Director Director May 09 Buy 11.08 114,440 1,267,995 31,818 05/11/22
WOODHOUSE DAVID J Chief Executive Offi.. Chief Executive Officer Dec 29 Option 7.92 17,654 139,820 17,654 12/30/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Dec 06 Option 1.44 69,444 99,999 923,893 12/07/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Dec 06 Sell 18.41 30,000 552,300 908,893 12/07/21
WOODHOUSE DAVID J Chief Executive Offi.. Chief Executive Officer Nov 18 Option 7.54 15,000 113,100 15,000 11/19/21
WOODHOUSE DAVID J Chief Executive Offi.. Chief Executive Officer Nov 18 Sell 20.02 15,000 300,300 11/19/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Sep 14 Sell 26.08 30,000 782,400 929,449 09/14/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Jan 06 Option 0.6 150,000 90,000 1,020,005 01/06/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Jan 06 Sell 29.77 25,000 744,250 870,005 01/06/21
CHEN JIN-LONG Chief Scientific Off.. Chief Scientific Officer Dec 16 Sell 28.22 25,000 705,500 895,005 12/16/20